Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2017

View Archived Issues

Heat Biologics set to acquire Pelican Therapeutics

Diamyd Medical invests in NextCell Pharma

Eurostars grant awarded to international consortium developing antibody-drug conjugates

YY-1 protein as a potential prognostic marker in Wilms' tumor

ImmunoMet Therapeutics raises series B financing

Inhibikase receives research grant from The Michael J. Fox Foundation

IDO-1, a potential biomarker for cancer of the biliary tract

Pharnext and Galapagos collaborate to generate pipeline of synergistic drug combinations

First-in-human study of AAGP-treated islet cells for type 1 diabetes

Beijing Hanmi Pharmaceutical patents IRAK-4 inhibitors

Karyopharm Therapeutics presents serine/threonine-protein kinase modulators

FORUM Pharmaceuticals discovers oxadiazine compounds

PKU HealthCare Industry Group presents phosphatidylinositol 3-kinase alpha inhibitors

Janssen Pharmaceutica identifies protein arginine N-methyltransferase 5 inhibitors

Bavarian Nordic and Roche collaborate to study Tecentriq with CV-301 for bladder cancer

Synairgen reports new data from LOXL2 enzyme inhibitor program in IPF

Vasodilator-stimulated phosphoprotein as potential diagnostic marker for papillary thyroid carcinoma

CD163-positive M2-like macrophages correlate with patient survival in esophageal adenocarcinoma

FDA clears IND for UCART-19

Zinplava approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...